LBL-007
Advanced Solid Tumors
Key Facts
About LakeShore Biopharma
LakeShore Biopharma (LSB) is a China-based, publicly traded biotech focused on oncology and autoimmune disorders. The company employs a portfolio-centric strategy, advancing a pipeline of monoclonal antibodies, ADCs, and small molecules through clinical development. Its core competency lies in identifying, in-licensing, and developing therapeutic candidates, aiming to deliver novel treatments in markets with high unmet need.
View full company profileAbout LakeShore Biopharma
LakeShore Biopharma (LSB) is a China-based, publicly traded biotech focused on oncology and autoimmune disorders. The company employs a portfolio-centric strategy, advancing a pipeline of monoclonal antibodies, ADCs, and small molecules through clinical development. Its core competency lies in identifying, in-licensing, and developing therapeutic candidates, aiming to deliver novel treatments in markets with high unmet need.
View full company profileTherapeutic Areas
Other Advanced Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| NT219 | Purple Biotech | Phase 1/2 |
| INDP-101 | Indaptus Therapeutics | Phase 1 |
| NST-101 (estimated) | Novastage Pharmaceuticals | Phase 1/2 |
| Meta10-TILs | Leman Biotech | Phase 1 |
| PM14 | PharmaMar | Phase 1/2 |
| Ecubectedin (PM54) | PharmaMar | Phase 1 |
| M8891 | Merck KGaA | Phase 1/2 |
| P-002 | Panacea Biotec | Phase 1/2 |
| Undisclosed kinase inhibitor | Tyligand Bioscience | Phase 1 |
| TYK-001 | TYK Medicines | Phase 1/2 |
| PT-112 | SciClone Pharmaceuticals | Phase 1 |
| AP-202 | Advance Pharmaceutical | Phase 1/2 |